The intricate world of pharmaceutical development hinges on the availability of precise and high-quality chemical building blocks. Among these, 6-Bromo-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole, identified by CAS number 1231930-33-8, stands out as a crucial intermediate. Its primary significance lies in its role in the synthesis of Abemaciclib, a targeted therapy that has revolutionized the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. For pharmaceutical researchers and manufacturers, understanding the properties and sourcing of this compound is vital.

Abemaciclib is a potent CDK4/6 inhibitor, and its complex molecular structure is assembled through a series of precise chemical reactions, with 6-Bromo-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole forming a core part of its backbone. The demand for this intermediate directly correlates with the growing application of Abemaciclib in clinical practice. Therefore, ensuring a stable and reliable supply of this high-purity intermediate is a strategic imperative for drug manufacturers. Reliable suppliers and manufacturers based in regions like China are key to meeting this demand effectively and affordably.

The chemical features of 6-Bromo-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole, including its specific arrangement of bromine, fluorine, and isopropyl groups on the benzo[d]imidazole core, are precisely what make it suitable for the subsequent steps in Abemaciclib synthesis. These structural elements dictate its reactivity and compatibility with other reagents in the synthetic pathway. Companies looking to buy this intermediate should verify its adherence to the chemical formula C11H12BrFN2 and its molecular weight of 271.13 g/mol, alongside stringent purity standards.

For companies in the pharmaceutical sector, securing a consistent supply of this key intermediate requires establishing strong relationships with trusted manufacturers. These manufacturers not only need to guarantee product quality and purity but also possess the capacity for scaling up production to meet commercial demands. Pricing is, of course, a significant consideration, and partnering with Chinese manufacturers often provides a competitive advantage due to efficient production processes and economies of scale. When sourcing, it is recommended to obtain quotes from multiple suppliers to compare prices and service offerings.

Furthermore, the pharmaceutical industry places a high emphasis on regulatory compliance and quality management systems. Manufacturers of pharmaceutical intermediates must demonstrate adherence to Good Manufacturing Practices (GMP) or similar quality standards. Buyers should actively seek manufacturers who can provide comprehensive documentation, including Certificates of Analysis (CoA), and are open to audits. The availability of this intermediate through custom synthesis services also presents opportunities for tailored procurement solutions.

In summary, 6-Bromo-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole is more than just a chemical compound; it is an enabler of advanced cancer therapies. Its availability and quality directly impact the production of Abemaciclib. By diligently selecting manufacturers and suppliers, especially those in China known for their robust chemical industries, pharmaceutical companies can ensure the consistent supply of this critical intermediate, thereby supporting ongoing efforts to combat cancer and improve patient outcomes. We encourage you to inquire about purchasing options and explore how our reliable manufacturing capabilities can meet your needs.